Eli Lilly (NYSE:LLY) recently announced promising Phase 1 data for its folate receptor alpha antibody-drug conjugate, ...

Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Aleniglipron’s tolerability could be a differentiator for Structure Therapeutics, but its efficacy lags competitors. Read why ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE ... With an EPS of $25.97 and a P/E ratio of 50 in 2028, we forecast the stock price to be $1,300.00. A slight dip in EPS growth ...

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

However, this forecast, 3% lower for revenue and ... investors should hold on buying more NVO stock, as it appears that Eli Lilly’s research expenses are to pay off even more in the obesity ...

What caused Eli Lilly's stock to fall this week? During an earnings report, management will generally provide investors with a forecast for the next quarter and potentially the full year.

DoorDash shares decreased after announcing downbeat first-quarter sales and analysts revising price forecasts. Get access to the leaderboards pointing to tomorrow’s biggest stock movers.

During the most recent episode of Mad Money, Jim Cramer opened the show by emphasizing just how much American companies ...

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...